The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism

BMC Cancer

Volumn 5, Issue , 2005, Pages

  Pajonk, Frank ^a   van Ophoven, Arndt ^b   Weissenberger, Christian ^c   McBride, William H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CASPASE 3; DNA DEPENDENT PROTEIN KINASE; DOUBLE STRANDED DNA; PROTEASOME; PROTEASOME INHIBITOR; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; CASP3 PROTEIN, HUMAN; CASPASE; CYSTEINE PROTEINASE INHIBITOR; DNA; DNA BINDING PROTEIN; LEUPEPTIN; NUCLEAR PROTEIN; PRKDC PROTEIN, HUMAN; PROTEINASE INHIBITOR; RADIOSENSITIZING AGENT;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA REPAIR; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYPOTHESIS; IONIZING RADIATION; MITOSIS INHIBITION; PROSTATE CANCER; RADIOSENSITIVITY; RADIOSENSITIZATION; DOSE RESPONSE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; IMMUNOBLOTTING; METABOLISM; TREATMENT OUTCOME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASES; CELL CYCLE; CELL LINE, TUMOR; CYSTEINE PROTEINASE INHIBITORS; DNA; DNA REPAIR; DNA-ACTIVATED PROTEIN KINASE; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; LEUPEPTINS; NUCLEAR PROTEINS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; RADIATION, IONIZING; RADIATION-SENSITIZING AGENTS; TREATMENT OUTCOME;

EID: 26844545414     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-5-76     Document Type: Article

References (69)

1. Caffo O, Doglioni C, Veronese S, Bonzanini M, Marchetti A, Buttitta F, Fina P, Leek R, Morelli L, Palma PD, Harris AL, Barbareschi M: Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res 1996, 2(9):1591-1599.
2. Bonin SR, Pajak TF, Russell AH, Coia LR, Paris KJ, Flam MS, Sauter ER: Overexpression of p53 protein and outcome of patients treated with chemoradiation for carcinoma of the anal canal: a report of randomized trial RTOG 87-04. Radiation Therapy Oncology Group. Cancer 1999, 85(6):1226-1233.
3. Hayakawa K, Mitsuhashi N, Hasegawa M, Saito Y, Sakurai H, Ohno T, Maebayashi K, Ebara T, Hayakawa KY, Niibe H: The prognostic significance of immunohistochemically detected p53 protein expression in non-small cell lung cancer treated with radiation therapy. Anticancer Res 1998, 18(5B):3685-3688.
4. Pomp J, Davelaar J, Blom J, van Krimpen C, Zwinderman A, Quint W, Immerzeel J: Radiotherapy for oesophagus carcinoma: the impact of p53 on treatment outcome. Radiother Oncol 1998, 46(2):179-184.
5. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL: Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994, 78(5):761-771.
6. Rolfe M, Chiu MI, Pagano M: The ubiquitin-mediated proteolytic pathway as a therapeutic area. J Mol Med 1997, 75(1):5-17.
7. Weissman AM: Regulating protein degradation by ubiquitination. Immunol Today 1997, 18(4):189-198.
8. Pajonk F, McBride WH: Ionizing radiation affects 26s proteasome function and associated molecular responses, even at low doses. Radiother Oncol 2001, 59(2):203-212.
9. Stempien-Otero A, Karsan A, Cornejo CJ, Xiang H, Eunson T, Morrison RS, Kay M, Winn R, Harlan J: Mechanisms of hypoxia-induced endothelial cell death. Role of p53 in apoptosis. J Biol Chem 1999, 274(12):8039-8045.
10. Kueckelkorn U, Knuehl C, Boes-Fabian B, Drung I, Kloetzel PM: The effect of heat shock on 20S/26S proteasomes. Biol Chem 2000, 381(9-10):1017-1023.
11. Pajonk F, van Ophoven A, McBride WH: Hyperthermia-induced proteasome inhibition and loss of androgen receptor expression in human prostate cancer cells. Cancer Res 2005, 65(11):4836-4843.
12. Glockzin S, von Knethen A, Scheffner M, Brune B: Activation of the cell death program by nitric oxide involves inhibition of the proteasome. J Biol Chem 1999, 274(28):19581-19586.
13. Hasselgren PO, Fischer JE: The ubiquitin-proteasome pathway: review of a novel intracellular mechanism of muscle protein breakdown during sepsis and other catabolic conditions. Ann Surg 1997, 225(3):307-316.
14. Tanaka K: Molecular biology of proteasomes. Mol Biol Rep 1995, 21(1):21-26.
15. Stohwasser R, Kloetzel PM: Cytokine induced changes in proteasome subunit composition are concentration dependent. Biol Chem 1996, 377(9):571-577.
16. Nandi D, Woodward E, Ginsburg DB, Monaco JJ: Intermediates in the formation of mouse 20S proteasomes: implications for the assembly of precursor beta subunits. EMBO J 1997, 16(17):5363-5375.
17. Schmidt M, Kloetzel PM: Biogenesis of eukaryotic 20S proteasomes: the complex maturation pathway of a complex enzyme. FASEB J 1997, 11(14):1235-1243.
18. Kloetzel PM, Soza A, Stohwasser R: The role of the proteasome system and the proteasome activator PA28 complex in the cellular immune response. Biol Chem 1999, 380(3):293-297.
19. Drexler HC: Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci U S A 1997, 94(3):855-860.
20. Wu LW, Reid S, Ritchie A, Broxmeyer HE, Donner DB: The proteasome regulates caspase-dependent and caspase-independent protease cascades during apoptosis of MO7e hematopoietic progenitor cells. Blood Cells Mol Dis 1999, 25(1):20-29.
21. Herrmann JL, Briones FJ, Brisbay S, Logothetis CJ, McDonnell TJ: Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene 1998, 17(22):2889-2899.
22. McDade TP, Perugini RA, Vittimberga FJJ, Callery MP: Ubiquitin-proteasome inhibition enhances apoptosis of human pancreatic cancer cells. Surgery 1999, 126(2):371-377.
23. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999, 59(11):2615-2622.
24. Zhang XM, Lin H, Chen C, Chen BD: Inhibition of ubiquitin-proteasome pathway activates a caspase-3-like protease and induces Bcl-2 cleavage in human M-07e leukaemic cells. Biochem J 1999, 340(Pt 1):127-133.
25. Kitagawa H, Tani E, Ikemoto H, Ozaki I, Nakano A, Omura S: Proteasome inhibitors induce mitochondria-independent apoptosis in human glioma cells. FEBS Lett 1999, 443(2):181-186.
26. Pajonk F, Pajonk K, McBride WH: Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition. Int J Radiat Oncol Biol Phys 2000, 47(4):1025-1032.
27. An B, Goldfarb RH, Siman R, Dou QP: Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 1998, 5(12):1062-1075.
28. Mortenson MM, Schlieman MG, Virudachalam S, Bold RJ: Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother Pharmacol 2004, 54(4):343-53.
29. Pasquini LA, Besio Moreno M, Adamo AM, Pasquini JM, Soto EF: Lactacystin, a specific inhibitor of the proteasome, induces apoptosis and activates caspase-3 in cultured cerebellar granule cells. J Neurosci Res 2000, 59(5):601-611.
30. Qiu JH, Asai A, Chi S, Saito N, Hamada H, Kirino T: Proteasome inhibitors induce cytochrome c-caspase-3-like protease-mediated apoptosis in cultured cortical neurons. J Neurosci 2000, 20(1):259-265.
31. Han Z, Malik N, Carter T, Reeves WH, Wyche JH, Hendrickson EA: DNA-dependent protein kinase is a target for a CPP32-like apoptotic protease. J Biol Chem 1996, 271(40):25035-25040.
32. Song Q, Burrows SR, Smith G, Lees-Miller SP, Kumar S, Chan DW, Trapani JA, Alnemri E, Litwack G, Lu H, Moss DJ, Jackson S, Lavin MF: Interleukin-1 beta-converting enzyme-like protease cleaves DNA- dependent protein kinase in cytotoxic T cell killing. J Exp Med 1996, 184(2):619-626.
33. Masdehors P, Omura S, Merle-Beral H, Mentz F, Cosset JM, Dumont J, Magdelenat H, Delic J: Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br J Haematol 1999, 105(3):752-757.
34. Kane RC, Bross PF, Farrell AT, Pazdur R: Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003, 8(6):508-513.
35. Maki RG, Kraft AS, Scheu K, Yamada J, Wadler S, Antonescu CR, Wright JJ, Schwartz GK: A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer 2005, 103(7):1431-1438.
36. Price N, Dreicer R: Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Prostate Cancer 2004, 3(3):141-143.
37. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ, Chatta G: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004, 22:2108-21.
38. Blaney SM, Bernstein M, Neville K, Ginsberg J, Kitchen B, Horton T, Berg SL, Krailo M, Adamson PC: Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol 2004, 22(23):4804-4809.
39. Kondagunta GV, Drucker B, Schwartz L, Bacik J, Marion S, Russo P, Mazumdar M, Motzer RJ: Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 2004, 22(18):3720-3725.
40. Shah MH, Young D, Kindler HL, Webb I, Kleiber B, Wright J, Grever M: Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2004, 10(18 Pt 1):6111-6118.
41. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001, 61(7):3071-3076.
42. Russo SM, Tepper JE, Baldwin ASJ, Liu R, Adams J, Elliott P, Cusack JCJ: Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001, 50(1):183-193.
43. Pajonk F, Pajonk K, McBride W: Apoptosis and radiosensitization of Hodgkin's cells by proteasome inhibition. Int J Radiat Oncol Biol Phys 2000, 47(4):1025-1032.
44. Lees-Miller SP, Sakaguchi K, Ullrich SJ, Appella E, Anderson CW: Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol Cell Biol 1992, 12(11):5041-5049.
45. Ihara M, Suwa A, Komatsu K, Shimasaki T, Okaichi K, Hendrickson EA, Okumura Y: Heat sensitivity of double-stranded DNA-dependent protein kinase (DNA- PK) activity. Int J Radiat Biol 1999, 75(2):253-258.
46. Enari M, Talanian RV, Wong WW, Nagata S: Sequential activation of ICE-like and CPP32-like proteases during Fas- mediated apoptosis. Nature 1996, 380(6576):723-726.
47. Machiels BM, Henfling ME, Gerards WL, Broers JL, Bloemendal H, Ramaekers FC, Schutte B: Detailed analysis of cell cycle kinetics upon proteasome inhibition. Cytometry 1997, 28(3):243-252.
48. Maity A, McKenna WG, Muschel RJ: The molecular basis for cell cycle delays following ionizing radiation: a review. Radiother Oncol 1994, 31(1):1-13.
49. Hwang A, Muschel RJ: Radiation and the G2 phase of the cell cycle. Radiat Res 1998, 150(5 Suppl):S52-9.
50. Lee DH, Goldberg AL: Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae. J Biol Chem 1996, 271(44):27280-27284.
51. Teraoka H, Yumoto Y, Watanabe F, Tsukada K, Suwa A, Enari M, Nagata S: CPP32/Yama/apopain cleaves the catalytic component of DNA-dependent protein kinase in the holoenzyme. FEBS Lett 1996, 393(1):1-6.
52. Dietrich C, Bartsch T, Schanz F, Oesch F, Wieser RJ: p53-dependent cell cycle arrest induced by N-acetyl-L-leucinyl-L- leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts. Proc Natl Acad Sci U S A 1996, 93(20):10815-10819.
53. Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivieres S, Mercep L, Ferrari S: Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 1998, 273(23):14424-14429.
54. Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K: Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci U S A 1999, 96(14):7797-7802.
55. Delic J, Masdehors P, Omura S, Cosset JM, Dumont J, Binet JL, Magdelenat H: The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis [see comments]. Br J Cancer 1998, 77(7):1103-1107.
56. Sinclair WK, Morton RA: X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 1966, 29(3):450-474.
57. Meyn RE, Stephens LC, Milas L: Programmed cell death and radioresistance. Cancer Metastasis Rev 1996, 15(1):119-131.
58. Weichselbaum RR, Little JB: The differential response of human tumours to fractionated radiation may be due to a post-irradiation repair process. Br J Cancer 1982, 46(4):532-537.
59. Rosenzweig KE, Youmell MB, Palayoor ST, Price BD: Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clin Cancer Res 1997, 3(7):1149-1156.
60. Chernikova SB, Wells RL, Elkind MM: Wortmannin sensitizes mammalian cells to radiation by inhibiting the DNA-dependent protein kinase-mediated rejoining of double-strand breaks. Radiat Res 1999, 151(2):159-166.
61. Hsieh CL, Arlett CF, Lieber MR: V(D)J recombination in ataxia telangiectasia, Bloom's syndrome, and a DNA ligase I-associated immunodeficiency disorder. J Biol Chem 1993, 268(27):20105-20109.
62. Jeggo PA: Identification of genes involved in repair of DNA double-strand breaks in mammalian cells. Radiat Res 1998, 150(5 Suppl):S80-91.
63. Allalunis-Turner MJ, Lintott LG, Barron GM, Day RS, Lees-Miller SP: Lack of correlation between DNA-dependent protein kinase activity and tumor cell radiosensitivity. Cancer Res 1995, 55(22):5200-5202.
64. Dikomey E, Borgmann K, Brammer I, Kasten-Pisula U: Molecular mechanisms of individual radiosensitivity studied in normal diploid human fibroblasts. Toxicology 2003, 193(1-2):125-135.
65. Olive PL, Banath JP, MacPhail HS: Lack of a correlation between radiosensitivity and DNA double-strand break induction or rejoining in six human tumor cell lines. Cancer Res 1994, 54(14):3939-3946.
66. Grimm LM, Goldberg AL, Poirier GG, Schwartz LM, Osborne BA: Proteasomes play an essential role in thymocyte apoptosis. Embo J 1996, 15(15):3835-3844.
67. Sadoul R, Fernandez PA, Quiquerez AL, Martinou I, Maki M, Schroter M, Becherer JD, Irmler M, Tschopp J, Martinou JC: Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons. Embo J 1996, 15(15):3845-3852.
68. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC: Advances in biology of multiple myeloma: clinical applications. Blood 2004, 104(3):607-618.
69. Monney L, Otter I, Olivier R, Ozer HL, Haas AL, Omura S, Borner C: Defects in the ubiquitin pathway induce caspase-independent apoptosis blocked by Bcl-2. J Biol Chem 1998, 273(11):6121-6131.